Prevalence of low semen quality including 95% confidence interval (CI) for medication at the ATC 5 level. by P.G.J. ter Horst (21743830)

Subjects:

Univariable and multivariable analyses (age- and abstinence days-adjusted), concerning a selection of medicaments with n ≥ 10 medicament users and p < 0.1 by univariate analysis.... by P.G.J. ter Horst (21743830)

Subjects:

Sphingolipid biosynthetic pathway. by Hala Tamim El Jarkass (16625309)

Subjects:

Lipidomic data from infected and uninfected adults and their embryos. by Hala Tamim El Jarkass (16625309)

Subjects:

All infection data from the study. by Hala Tamim El Jarkass (16625309)

Subjects:

597 SNPs for the candidate gene approach. by Dai Nogimura (21445649)

Subjects:

Definitions of traits for association analyses. by Dai Nogimura (21445649)

Subjects:

Age and sex distribution of the participants. by Dai Nogimura (21445649)

Subjects:

Top 10 significant functional annotations of down-regulated DEGs. by Meitner Cadena (22216261)

“…Functional annotations are ordered by decreasing significance, with color indicating significance level based on the legend’s color scale, the ratio of genes on the horizontal axis, and DEG count represented by circle size.…”

Intrauterine supplementation of <i>Kif15</i> in E15 <i>Kif15</i>^<i>-/-</i> mice rescued the distribution of PSD95 in <i>Kif15</i>^<i>-/-</i> PFC neurons. by Xiaomei He (795333)

Subjects:

Distribution of SNPs and their frequencies based on mutation classes. by Sadia Afrin Runa (22504971)

Subjects:

Characteristics of study subjects. by Jung Eun Choi (563339)

Subjects:

Changes in the white blood cell count. by Lu Yang (30847)

“…The leukocyte and neutrophil counts of the patients in the bone pain group were significantly higher than those of the patients in the no bone pain group, P(WBC) = 0.001, P(ANC) = 0.002.…”

Analysis of randomized controlled trials stratified based on treatment duration. by Solima Sabeel (9545738)

Subjects:

Detailed table of sandstones mechanical parameters change. by Wenyu Lv (20139458)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

CONSORT 2025 Flow Diagram [70]. by Robert Trybulski (10998702)

Subjects:

(A) Side image of epoxy resin-made abutment-analog base and prosthesis; (B) Front image of epoxy resin-made abutment-analog base and prosthesis. by Long Li (6555)

Subjects:

RcbA and RcbB co-operatively decrease motility independent of CaCl₂ concentration. by Shobnom Mustaree (21728815)

Log2 fold change (FC), mean and standard deviation (SD) of each lipid specie from the normal liver (NL) and simple steatosis (SS) groups, and adjusted p-values. by Laia Bertran (3685147)